Intellia Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

CEO

John M. Leonard

CEOJohn M. Leonard

Employees

403

Employees403

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2014

Founded2014

Employees

403

Employees403

NTLA Key Statistics

Market cap

1.25B

Market cap1.25B

Price-Earnings ratio

-2.44

Price-Earnings ratio-2.44

Dividend yield

—

Dividend yield—

Average volume

4.22M

Average volume4.22M

High today

$11.95

High today$11.95

Low today

$11.41

Low today$11.41

Open price

$11.60

Open price$11.60

Volume

3.75M

Volume3.75M

52 Week high

$23.76

52 Week high$23.76

52 Week low

$5.90

52 Week low$5.90

NTLA News

TipRanks 20h

Cathie Wood’s ARK Investment buys 185.2K shares of Intellia Therapeutics today

20:07 EDT Cathie Wood’s ARK Investment buys 185.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time,...

TipRanks 6d

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?

Regeneron Pharmaceuticals ((REGN)), Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Tak...

Analyst ratings

75%

of 28 ratings

Buy

75%

Hold

21.4%

Sell

3.6%

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.